Table 2 Independent review committee-assessed response (full analysis population).

From: Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study

Response category

Lyophilised belantamab mafodotin 3.4 mg/kg (N = 25)

Best response

Very good partial response (VGPR)

6 (24)

Partial response (PR)

7 (28)

Minimal response (MR)

1 (4)

Stable disease

4 (16)

Progressive disease

6 (24)

Not evaluable

1 (4)

Overall response rate (ORR)a

13 (52) (95% CI: 31.3–72.2)

Clinical benefit rate (CBR)b

14 (56) (95% CI: 34.9–75.6)

  1. Data are n (%) unless otherwise specified. No patients had stringent complete response (sCR) or complete response (CR).
  2. aORR included sCR+CR + VGPR + PR.
  3. bCBR included sCR+CR + VGPR + PR + MR.
Back to article page